Take as Directed

We crossed much sensitive and difficult ground in our extended conversation with Rep. Tom Cole (R-OK). President Trump’s bout with Covid-19, the proliferation of White House cases, the claim that the virus is not dangerous: how to make sense of all of this this, and the implications? Why have negotiations over the next Covid-19 emergency spending bill broken down? And how bad are the consequences? How to protect CDC and FDA? Do we need a national conversation on the value and merits of vaccines, and the need to rebuild popular trust and confidence? Should Congress support Gavi to bring vaccines to low and middle income countries? Give a listen. 

Rep. Tom Cole (R-OK) is leading force in Congress advocating for strong bipartisan US leadership in health security, at home and abroad. He is the former Chair and now Ranking Member of the Appropriations Subcommittee on Labor, HHS, Education and Related Agencies. He is Ranking member of the Rules Committee and Deputy Whip of the Republican Conference. He is also a member of the CSIS Commission on Strengthening America’s Health Security.

Our longstanding friend and ally Judyth Twigg joins us to survey the rather bumpy ride that America’s colleges and universities are experiencing as they navigate the pandemic. Are these institutions the new super-spreaders? What form of leadership is showing the best results? Are colleges and universities now the center for innovation in testing? How well exactly do we learn when separated into remote settings? What about mental health? 

Professor Judyth Twigg is Professor of Political Science at Virginia Commonwealth University and CSIS non-resident Senior Fellow with the Global Health Policy Center and Europe Program.

We sat with Chris Murray for an intense conversation on IHME’s recent, startling (and controversial) forecast that the United States would experience a dramatic surge in Covid-19 infections and deaths by year’s end that will exceed the peak moments of April. Many of the drivers are behavioral – a decline in mask use, rising mobility, lower vigilance and social distancing. But the seasonality is what will truly turbocharge the pandemic. Why is that, and what gives confidence that seasonality will be so powerful? Why do we as a nation appear stuck on a roller-coaster, incapable of learning to stick with actions that work?

Chris Murray is Director of the Institute for Health Metrics and Evaluation (IHME) and Chair, Department of Health Metrics Sciences, at the University of Washington

In this episode, we learn from Richard Rossow, CSIS Wadhwani Chair in U.S.-India Policy Studies. India now ranks second in the world in Covid-19 cases, and in a single recent day recorded over 90,000 cases. What explains this dramatic, startling surge that we are witnessing? And how to reconcile that with the Modi’s government’s continued determination to reopen society and the economy? And his continued high public standing? And how does this relate to India’s special place in the world in production of generic vaccines?

Richard Rossow is a senior adviser and holds the Wadhwani Chair in U.S.-India Policy Studies at CSIS.

We gather to discuss with Dr. Heidi Larson about her new book, Stuck: How Vaccine Rumors Start – and Why they Don’t Go Away, a wake-up call and appeal to re-think what drives popular distrust in science and rising levels of vaccine refusal and hesitancy. As the world strives to develop safe and effective vaccines to arrest the Covid-19 pandemic, we should expect widespread resistance. How should our understanding of rumors, risks and uncertainty, digital wildfires, and group think figure in our thinking? Popular trust in vaccines and authority have national security implications, given the urgent, huge stake in getting control of the pandemic and restoring economies: what might that mean? What type of engagement is most needed and appropriate today, if we are to avoid repeating the mistakes of the past? 

Dr. Heidi Larson is Professor of Anthropology, Risk and Decision Science and Director of the Vaccine Confidence Project at the London School of Hygiene and Tropical Medicine.

Both the Democratic and Republican Conventions had to give a central prominence to the pandemic, but chose radically different approaches, story lines, and messages. Two conventions, two realities. Listen as Steve and Andrew work through these divergences and what they presage as we head towards November 3.

 In the global scramble for Covid-19 vaccines, dominated by aggressive nationalist approaches, COVAX has emerged as a promising, nascent, international initiative to develop and equitably distribute Covid-19 vaccines to benefit all countries. In this episode, Steve is joined by Nikolaj Gilbert, President and CEO at PATH; Peggy Hamburg, former Commissioner of the FDA; Kendall Hoyt, Assistant Professor of Medicine at Dartmouth University's Giesel School of Medicine; and Nicole Lurie, Strategic Advisor to the CEO at the Coalition for Epidemic Preparedness Innovations (CEPI) for a discussion about COVAX and its prospects for success. How does it work? What will it cost? What will it take for COVAX to succeed? What role can the United States play in that effort? The panelists discuss these issues and the implications they may have on the trajectory of the pandemic in the United States and around the world. This episode is a condensed version of an August 11 event hosted by the CSIS Commission on Strengthening America’s Health Security: “The Scramble for Vaccines and the COVAX Facility.”

Steve joined with CSIS Senior Vice President Heather Conley and Professor Judyth Twigg, Virginia Commonwealth University, to discuss the fast-breaking controversy of this week, as Russia announced it had registered the first Covid-19 vaccine, without first conducting large late-stage human trials, and would soon commence mass immunizations, in Russia and beyond. What domestic and international calculations are motivating Vladimir Putin? What are the risks and barriers? Might the vaccine succeed, might Putin succeed in changing the rules? What might this mean for the United States and China in their respective quest to be victors in the global race? For WHO as it strives to preserve common norms?

In this episode, Steve is joined by two members of the global health team to discuss their new commentary on the race for a Covid-19 vaccine: Katherine Bliss, GHPC Senior Fellow and Anna Carroll, GHPC Associate Fellow. Nationalism among the wealthier and more powerful countries dominates the global scramble for a vaccine. They have locked up much of the future production of promising vaccines, while low and middle income countries are at risk of being left empty-handed and uncertain, at the back of the queue. One emerging and promising initiative is the COVAX vaccine facility, led by Gavi and the Coalition for Epidemic Preparedness Innovations (CEPI), which seeks to ensure timely access and equity to vaccines, under the broad umbrella of the ACT-Accelerator. What’s the rationale for these efforts, how are they structured and financed, and what is required to sustain them and put them on a path to success? Who are its strongest supporters? And what is the national security case for the United States pursuing a blend of both nationalism and internationalism, in support of COVAX. What specifically are we arguing that the United States should do?

What happens at the state level can be profoundly decisive. Steve sat with Rep. Peter Welch to discuss how Vermont became such a dramatic outlier, in its quick and effective control of the coronavirus, and the actions taken to preserve those gains. The conversation quickly migrated to Vermont’s state political leadership, the predisposition to respect science, the centrality of social trust and political culture, and those measures most effective in keeping families and businesses intact. “Everyone is eager for a vaccine.” Dr. Fauci represents “science, public health, and expertise.” Hope rests in solidarity, “collective mutual support.” 

Rep. Peter Welch (D-VT) was first elected to represent the citizens of Vermont in 2006.